An Antagonist Antibody That Inhibits Cancer Cell Growth In Vitro through RACK1
These findings suggest that RACK1 plays a crucial role in tumor cell cycling and could represent a novel therapeutic target for cancer treatment. Although RACK1 is recognized as a significant target protein in various tumors, no commercial therapeutic agents currently exist. Our results suggest that the H9 antibody could be a promising candidate for the development of novel cancer therapies.
Authors
- Kyung Ho Han (ORCID: https://orcid.org/0000-0001-6907-1462)
- Ji Hoe Kim
- Eun Ji Lee (ORCID: https://orcid.org/0000-0001-6464-8955)
Institutions
- Hannam University (KR)
Publication Details
- Journal
- Pharmaceuticals
- Published
- 2024-09-30
- DOI
- https://doi.org/10.3390/ph17101303
- Citations
- 2
- Primary Topic
- Ubiquitin and proteasome pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.47